Search

The Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC) identified the need to update the current guidelines and worked to produce this document, which should serve to guide clinicians managing children with juvenile idiopathic arthritis associated uveitis (JIAU) and idiopathic chronic anterior uveitis (CAU).The group analysed the literature published between December 2014- June 2020 after a systematic literature review conducted by two clinicians. Paediatric rheumatologists were paired with ophthalmologists to review the eligible 37 publications. The search criteria were selected to reflect those used for the 2018 SHARE recommendations in order to provide an update, rather than a replacement for that publication. The consensus meeting was moderated by Prof Dan Furst MD, UCLA, Los Angeles, USA. The summary of the current evidence for each SHARE recommendation was presented to the expert committee. These were then discussed and revised during a video consensus meeting on the 22JIAU treatment was extended to include CAU. Fourteen recommendations regarding treatment of JIAU und CAU with 80% agreement were accepted.An update to the previous 2018 SHARE recommendations for the treatment of children with JIAU with the addition of CAU was created using an evidence-based consensus process. This guideline should help support clinicians to care for children and young people with chronic anterior uveitis.

Objective.Data on uveitis in juvenile psoriatic arthritis (JPsA), a category of juvenile idiopathic arthritis (JIA), are scarce. We describe prevalence and risk factors for JPsA-associated uveitis (JPsA-U).Methods.Cross-sectional data from the German National Pediatric Rheumatological Database (2002–2014) were used to characterize JPsA-U and assess risk factors for the development of uveitis.Results.Uveitis developed in 6.6% of 1862 patients with JPsA. Patients with JPsA-U were more frequently female (73.0 vs 62.9%, P = 0.03), antinuclear antibody (ANA) positive (60.3 vs 37.0%, P < 0.001), younger at JPsA onset (5.3 ± 4.1 vs 9.3 ± 4.4 yrs, P < 0.001), and treated with disease-modifying antirheumatic drugs (DMARDs) significantly more frequently compared with JPsA patients without uveitis. On a multivariable analysis of a subgroup of 655 patients enrolled in the study ≤ 1 year after arthritis onset, mean clinical Juvenile Arthritis Disease Activity Score for 10 joints during study documentation was significantly associated with uveitis development. Children with early onset of JPsA (aged < 5 yrs vs ≥ 5 yrs) were significantly more frequently ANA positive (48.4% vs 35.7%, P < 0.001), affected by uveitis (17.3% vs 3.8%, P < 0.001), and treated with DMARDs (52.9% vs 43.8%, P < 0.001), but less often affected by skin disease (55.3% vs 61.0%, P = 0.03).Conclusion.The characteristics of patients with JPsA developing uveitis are similar to those of patients with uveitis in other JIA categories, such as oligoarticular JIA. Children with early-onset JPsA are at a higher risk for ocular involvement. Our data support the notion of a major clinical difference between those patients with early vs late onset of JPsA.